Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

NCT00409578 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1101

Enrollment

INDUSTRY

Sponsor class

Conditions

Post Acute Coronary Syndrome
Myocardial Ischemia

Interventions

DRUG: Placebo
DRUG: Aliskiren 300 mg
DRUG: Valsartan 320 mg
DRUG: Aliskiren/valsartan 300/320 mg

Sponsor

Novartis

Collaborators

[object Object]